Testing L608 for digital ulcers linked to systemic sclerosis
Tests L608 against placebo in adults with systemic sclerosis-associated digital ulcers.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers
Key facts
- Phase
- Phase 2
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pharmosa Biopharm Inc.
- Trial code
- NCT07925619
- Record updated
- 9 November 2026
- Original description
This trial is designed to evaluate the efficacy and safety of L608 compared to placebo in patients with SSc-DU.Read full original descriptionShow less
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of L608 Suspension in Patients With Systemic Sclerosis-associated Digital Ulcers
This trial is designed to evaluate the efficacy and safety of L608 compared to placebo in patients with SSc-DU.
Inclusion: Diagnosed with systemic sclerosis per ACR/EULAR 2013 criteria; Presence of at least one visible, painful digital ulcer; Participants aged ≥18 years.
Exclusion: Active gangrene (within 3 months) or active DU infection requiring treatment (within 1 month) prior to screening; Other rheumatic diseases are permitted if SSc is the predominant condition associated with DUs; DUs not primarily ischemic in origin.